Aerovate Therapeutics Inc


Prices are adjusted according to historical splits.

Aerovate Therapeutics Inc Stock Price


Today's Low:
Today's High:
Open Price:
52W Low:
52W High:
Prev. Close:

Company Statistics

Market Cap.:
$518.68 million
Book Value:
Revenue TTM:
Operating Margin TTM:
Gross Profit TTM:
Profit Margin:
Return on Assets TTM:
Return on Equity TTM:

Company Profile

Aerovate Therapeutics Inc had its IPO on 2021-06-30 under the ticker symbol AVTE.

The company operates in the Healthcare sector and Biotechnology industry. Aerovate Therapeutics Inc has a staff strength of 33 employees.

Stock update

Shares of Aerovate Therapeutics Inc opened at $21.08 at the start of the last trading session i.e. 2023-03-23.

The stocks traded within a range of $20.41 - $21.67, and closed at $21.67.

This is a +2.8% increase from the previous day's closing price.

A total volume of 44,668 shares were traded at the close of the day’s session.

In the last one week, shares of Aerovate Therapeutics Inc have slipped by -1.41%.

Aerovate Therapeutics Inc's Key Ratios

Aerovate Therapeutics Inc has a market cap of $518.68 million, indicating a price to book ratio of 4.5483 and a price to sales ratio of 0.

In the last 12-months Aerovate Therapeutics Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-45597000. The EBITDA ratio measures Aerovate Therapeutics Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Aerovate Therapeutics Inc’s operating margin was 0% while its return on assets stood at -17.2% with a return of equity of -28.03%.

In Q3, Aerovate Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Aerovate Therapeutics Inc’s PE and PEG Ratio

Forward PE
Trailing PE

Its diluted EPS in the last 12-months stands at $-1.62 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Aerovate Therapeutics Inc’s profitability.

Aerovate Therapeutics Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -10.778. Its price to sales ratio in the trailing 12-months stood at 0.

Aerovate Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$147.66 million
Total Liabilities
$7.71 million
Operating Cash Flow
$4.65 million
Capital Expenditure
Dividend Payout Ratio

Aerovate Therapeutics Inc ended 2023 with $147.66 million in total assets and $0 in total liabilities. Its intangible assets were valued at $147.66 million while shareholder equity stood at $139.14 million.

Aerovate Therapeutics Inc ended 2023 with $0 in deferred long-term liabilities, $7.71 million in other current liabilities, 2000.00 in common stock, $-72881000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $22.42 million and cash and short-term investments were $142.58 million. The company’s total short-term debt was $379,000 while long-term debt stood at $0.

Aerovate Therapeutics Inc’s total current assets stands at $145.16 million while long-term investments were $0 and short-term investments were $120.16 million. Its net receivables were $0 compared to accounts payable of $4.54 million and inventory worth $0.

In 2023, Aerovate Therapeutics Inc's operating cash flow was $4.65 million while its capital expenditure stood at $33000.

Comparatively, Aerovate Therapeutics Inc paid $0 in dividends in 2023.

Other key metrics

Current Trading Price
52-Week High
52-Week Low
Analyst Target Price

Aerovate Therapeutics Inc stock is currently trading at $21.67 per share. It touched a 52-week high of $30.79 and a 52-week low of $30.79. Analysts tracking the stock have a 12-month average target price of $33.8.

Its 50-day moving average was $23.84 and 200-day moving average was $20.52 The short ratio stood at 7.49 indicating a short percent outstanding of 0%.

Around 23.9% of the company’s stock are held by insiders while 11147.1% are held by institutions.

Frequently Asked Questions About Aerovate Therapeutics Inc

The stock symbol (also called stock or share ticker) of Aerovate Therapeutics Inc is AVTE

The IPO of Aerovate Therapeutics Inc took place on 2021-06-30

Similar Industry Stocks (Biotechnology)

Last Price
AltaGas Ltd (ATGFF)
LumiraDx Ltd (LMDX)
Uxin Ltd (UXIN)

Most Active

Last Price
Boxed Inc (BOXD)
Tesla Inc (TSLA)

Top Gainers

Last Price

Top Losers

Last Price
Imara Inc (IMRA)


Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.


930 Winter Street, Waltham, MA, United States, 02116